EP3458038A4 - Transporteurs d'oxygène réduit et leur utilisation destinés au traitement de la carboxyhémoglobinémie - Google Patents

Transporteurs d'oxygène réduit et leur utilisation destinés au traitement de la carboxyhémoglobinémie Download PDF

Info

Publication number
EP3458038A4
EP3458038A4 EP17800268.9A EP17800268A EP3458038A4 EP 3458038 A4 EP3458038 A4 EP 3458038A4 EP 17800268 A EP17800268 A EP 17800268A EP 3458038 A4 EP3458038 A4 EP 3458038A4
Authority
EP
European Patent Office
Prior art keywords
carboxyhemoglobinemia
conveyors
treatment
reduced oxygen
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP17800268.9A
Other languages
German (de)
English (en)
Other versions
EP3458038A1 (fr
EP3458038B1 (fr
Inventor
Jason Joseph ROSE
Qinzi XU
Mark T. Gladwin
Jesus TEJERO BRAVO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of EP3458038A1 publication Critical patent/EP3458038A1/fr
Publication of EP3458038A4 publication Critical patent/EP3458038A4/fr
Application granted granted Critical
Publication of EP3458038B1 publication Critical patent/EP3458038B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01C—AMMONIA; CYANOGEN; COMPOUNDS THEREOF
    • C01C3/00—Cyanogen; Compounds thereof
    • C01C3/08—Simple or complex cyanides of metals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP17800268.9A 2016-05-19 2017-05-19 Transporteurs d'oxygène réduit et leur utilisation destinés au traitement de la carboxyhémoglobinémie Active EP3458038B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662338870P 2016-05-19 2016-05-19
PCT/US2017/033607 WO2017201447A1 (fr) 2016-05-19 2017-05-19 Transporteurs d'oxygène réduit et leur utilisation destinés au traitement de la carboxyhémoglobinémie

Publications (3)

Publication Number Publication Date
EP3458038A1 EP3458038A1 (fr) 2019-03-27
EP3458038A4 true EP3458038A4 (fr) 2020-02-12
EP3458038B1 EP3458038B1 (fr) 2025-12-10

Family

ID=60325660

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17800268.9A Active EP3458038B1 (fr) 2016-05-19 2017-05-19 Transporteurs d'oxygène réduit et leur utilisation destinés au traitement de la carboxyhémoglobinémie

Country Status (7)

Country Link
US (2) US10973883B2 (fr)
EP (1) EP3458038B1 (fr)
JP (4) JP7113514B2 (fr)
CN (1) CN109475511A (fr)
AU (4) AU2017267955B2 (fr)
CA (1) CA3024171A1 (fr)
WO (1) WO2017201447A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021034416A2 (fr) 2019-07-02 2021-02-25 Hbo2 Therapeutics, Llc Mélanges de substitution d'hémoglobine comprenant du plasma reconstitué et des plaquettes, leur fabrication et leur utilisation
CN110522904A (zh) * 2019-09-09 2019-12-03 润方（北京）生物医药研究院有限公司 一种抑制血压升高的聚合血红蛋白
EP4149882A4 (fr) * 2020-05-11 2024-08-28 University of Pittsburgh - of the Commonwealth System of Higher Education Piégeurs de monoxyde de carbone à base de protéines rcom et préparations pour le traitement de l'empoisonnement au monoxyde de carbone
JP7811760B2 (ja) * 2020-08-28 2026-02-06 慶應義塾 メトヘモグロビン小胞体を有効成分として含む医薬およびその使用
JPWO2023068193A1 (fr) * 2021-10-18 2023-04-27

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE420841B (sv) 1975-07-11 1981-11-02 British Gas Corp Cirkulationssmort berlager
JPS5619500U (fr) 1979-07-24 1981-02-20
US4602987A (en) * 1984-09-24 1986-07-29 Aquanautics Corporation System for the extraction and utilization of oxygen from fluids
JP2573479B2 (ja) 1984-09-24 1997-01-22 アクワノ−テイクス・コ−ポレイシヨン 流体から酸素その他のリガンドを抽出利用するためのシステム
GB8710598D0 (en) 1987-05-05 1987-06-10 Star Medical Diagnostics Ltd Hemoglobin based blood substitute
JPH0459735A (ja) * 1990-06-27 1992-02-26 Terumo Corp ヘモグロビン含有リポソーム
DE19701037A1 (de) * 1997-01-15 1998-07-16 Sanguibiotech Ag Mit Schutzliganden der Sauerstoffbindungsstellen versehene Hämoglobine als künstliche Sauerstoffträger zur direkten biologisch-medizinischen Anwendung und Verfahren zu ihrer Herstellung
US5900402A (en) * 1997-05-29 1999-05-04 Enzon, Inc. Method of reducing side effects associated with administration of oxygen-carrying proteins
JP3945428B2 (ja) 2003-03-14 2007-07-18 ニプロ株式会社 ポルフィリン化合物、そのアルブミン包接化合物および人工酸素運搬体
JP2004307404A (ja) 2003-04-08 2004-11-04 Nipro Corp 人工酸素運搬体を含む医薬組成物
JP2006325833A (ja) 2005-05-25 2006-12-07 Hidetoshi Tsuchida 血中微粒子製剤の除去装置
US20090117207A1 (en) * 2005-11-29 2009-05-07 Zoltani Csaba K Methods and compositions for treatment of poison-caused pathology
US7504377B2 (en) * 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
DE102008045152A1 (de) * 2008-07-09 2010-01-14 Universität Duisburg-Essen Künstliche Sauerstoffträger und ihre Verwendung
JP2010194475A (ja) 2009-02-26 2010-09-09 Doshisha 一酸化炭素除去剤
NO2440239T3 (fr) 2009-06-09 2018-02-10
US10172950B2 (en) * 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US9114109B2 (en) * 2009-06-16 2015-08-25 University of Pittsburgh—of the Commonwealth System of Higher Education Five-coordinate neuroglobin and use thereof as a blood substitute
JP5619500B2 (ja) 2010-07-12 2014-11-05 学校法人同志社 シアン解毒剤
JP5619599B2 (ja) * 2010-12-28 2014-11-05 三菱重工業株式会社 電子料金収受システム
CN105209060B (zh) * 2013-03-15 2018-12-07 高等教育联邦系统-匹兹堡大学 用于治疗碳氧血红蛋白血症的组合物和方法
IS2934B (is) 2013-09-25 2016-01-15 Háskóli Íslands Mólýbden efnasambönd til notkunar við meðferð á sýaníðeitrun
WO2015179344A1 (fr) 2014-05-22 2015-11-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Utilisation de microperoxidases pour le traitement de la carboxyhémoglobinémie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
EP3458038A1 (fr) 2019-03-27
JP7113514B2 (ja) 2022-08-05
AU2020267259B2 (en) 2021-06-24
CN109475511A (zh) 2019-03-15
AU2024219773A1 (en) 2024-10-10
AU2017267955B2 (en) 2020-08-13
EP3458038B1 (fr) 2025-12-10
WO2017201447A1 (fr) 2017-11-23
JP2021191788A (ja) 2021-12-16
AU2021203348A1 (en) 2021-06-24
AU2017267955A1 (en) 2018-11-29
US12251427B2 (en) 2025-03-18
JP2023065549A (ja) 2023-05-12
US20210205419A1 (en) 2021-07-08
JP2019521966A (ja) 2019-08-08
US20190290739A1 (en) 2019-09-26
CA3024171A1 (fr) 2017-11-23
AU2021203348B2 (en) 2024-06-20
AU2020267259A1 (en) 2020-12-10
US10973883B2 (en) 2021-04-13
JP2024153951A (ja) 2024-10-29

Similar Documents

Publication Publication Date Title
IL293783A (en) Compounds and compositions for treating hematological disorders
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3866941C0 (fr) Manette de jeu ergonomique et système
EP3390443A4 (fr) Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
EP3370748A4 (fr) Microbiote thérapeutique pour le traitement et/ou la prévention de l'allergie alimentaire
EP3240804A4 (fr) Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
EP3362060A4 (fr) Biomarqueurs associés au diabète et de traitement d'affections associées au diabète
EP3512517A4 (fr) Utilisation de pridopidine pour le traitement de l'anxiété et de la dépression
EP3328429A4 (fr) Peptides et anticorps pour l'élimination de biofilms
MA42657A (fr) Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
IL280827A (en) Integrin alpha 4 antagonists and compositions comprising same for use in treating ocular conditions
EP3458038A4 (fr) Transporteurs d'oxygène réduit et leur utilisation destinés au traitement de la carboxyhémoglobinémie
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
EP3394098A4 (fr) Anticorps anti-myostatine et procédés d'utilisation
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
EP3331526A4 (fr) Enzymes de dégradation de la nicotine pour le traitement d'une dépendance à la nicotine et d'un empoisonnement à la nicotine
MA43361A (fr) Composition pour le soin et la protection de cultures
EP3294911A4 (fr) Plateforme de découverte et d'analyse d'agents thérapeutiques
EP3528820A4 (fr) Nouvelles formulations liposomales pegylées d'apeline pour le traitement de maladies liées au système cardiovasculaire
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
EP3346950A4 (fr) Générateur d'oxygène implantable et transporteur
EP3565518C0 (fr) Composition anhydre solide pour le soin et/ou le maquillage de matières kératiniques
EP3731810A4 (fr) Composition anhydre solide pour le soin et/ou le maquillage de matières kératiniques
EP3558293C0 (fr) Petites molécules inhibitrices de l'activité de la protéine sox18 dans le traitement de maladies associées à l'angiogenèse et/ou à la lymphangiogenèse
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200114

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 39/02 20060101ALI20200108BHEP

Ipc: A61K 31/02 20060101AFI20200108BHEP

Ipc: A61K 38/42 20060101ALI20200108BHEP

Ipc: A61K 35/14 20150101ALI20200108BHEP

Ipc: C01C 3/08 20060101ALI20200108BHEP

Ipc: C07K 14/795 20060101ALI20200108BHEP

Ipc: C01B 32/40 20170101ALI20200108BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40008038

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240710

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20250711

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: UPC_APP_9484_3458038/2025

Effective date: 20251009

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: F10

Free format text: ST27 STATUS EVENT CODE: U-0-0-F10-F00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251210

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017093099

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20260312

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251210

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251210

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251210

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20251210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20260310

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20260309

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251210